Abstract
Astragaloside IV (AS-IV), the major pharmacological extract from Astragalus membranaceus Bunge, possesses a variety of biological activities in the cardiovascular systems. Here, we aimed to evaluate preclinical evidence and possible mechanism of AS-IV for animal models of myocardial ischemia/reperfusion (I/R) injury. Studies of AS-IV in animal models with myocardial I/R injury were identified from 6 databases from inception to May, 2018. The methodological quality was assessed by using CAMARADES 10-item checklist. All the data were analyzed using Rev-Man 5.3 software. As a result, 22 studies with 484 animals were identified. The quality score of studies ranged from 3 to 6 points. Meta-analyses showed AS-IV can significantly decrease the myocardial infarct size and left ventricular ejection fraction, and increase shortening fraction compared with control group (P < 0.01). Significant decreasing of cardiac enzymes and cardiac troponin and increasing of decline degree in ST-segment were reported in one study each (P < 0.05). Additionally, the possible mechanisms of AS-IV for myocardial I/R injury are promoting angiogenesis, improving the circulation, antioxidant, anti-inflammatory and anti-apoptosis. Thus, AS-IV is a potential cardioprotective candidate for further clinical trials of myocardial infarction.
Highlights
Acute myocardial infarction (AMI) was one of the leading causes of morbidity and mortality worldwide (Dariush et al, 2016)
Astragaloside IV for Myocardial Ischemia/Reperfusion Injury that induced by ischaemia alone (Maria et al, 2016)
Astragaloside IV (AS-IV) (Figure 1) is one of the major and active components isolated from Astragalus membranaceus Bunge for tonifying Qi, and is a lanolin alcohol-shaped tetracyclic triterpenoid saponin with high polarity
Summary
Acute myocardial infarction (AMI) was one of the leading causes of morbidity and mortality worldwide (Dariush et al, 2016). Acute interruption of coronary artery led to cardiomyocyte ischaemia and apoptosis (Luo et al, 2015). Invasive vascular reconstructions such as percutaneous coronary intervention and coronary artery bypass grafting can improve coronary perfusion (Richard, 2011), and they were widely adopted after weighing the risks of invasive diagnostics and the benefits in terms of diagnostic accuracy, risk stratification and assessment of the risks related to revascularization (Damman et al, 2015). Astragaloside IV for Myocardial Ischemia/Reperfusion Injury that induced by ischaemia alone (Maria et al, 2016). Recent experimental studies (Ren et al, 2013; Li et al, 2017) demonstrated that AS-IV had pleiotropic anti-ischemic properties against focal cerebral ischemia/reperfusion injury, cardiovascular disease, pulmonary disease, liver fibrosis and diabetic nephropathy.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
